Lancet. 2025 Jan 30;405(10476):396-407. IF: 98.4
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02715-6
Lancet. 2025 Jan 30;405(10476):356-358. IF: 98.4
Rethinking surveillance after breast cancer.
www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00093-5
人工智能解读
JAMA. 2025 Jan 30. IF: 63.1
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
www.jamanetwork.com/journals/jama/fullarticle/2829800
JAMA. 2025 Jan 30. IF: 63.1
Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative Breast Cancer.
www.jamanetwork.com/journals/jama/fullarticle/2829805
J Clin Oncol. 2025 Jan 30. IF: 42.1
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
www.ascopubs.org/doi/10.1200/JCO-24-01360
Lancet Oncol. 2025 Jan 30. IF: 41.6
Discussions on the future of cancer care at the World Economic Forum in 2025.
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00062-2
Nat Cancer. 2025 Jan 30;6(1):24-40. IF: 23.5
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.
www.nature.com/articles/s43018-024-00893-z
Nat Cancer. 2025 Jan 30. IF: 23.5
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.
www.nature.com/articles/s43018-024-00891-1
Neuro Oncol. 2025 Jan 30. IF: 16.4
Tumor cells upregulate neurotransmitter GABA in the choroid plexus through STAT6-Bestrophin1 signaling, promoting leptomeningeal dissemination.
www.academic.oup.com/neuro-oncology/article/7990629
Nat Commun. 2025 Jan 30;16(1):1183. IF: 14.7
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.
www.nature.com/articles/s41467-025-56420-w
JAMA Netw Open. 2025 Jan 2;8(1):e2457336. IF: 10.5
Transportation Insecurity, Social Support, and Adherence to Cancer Screening.
www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829723
NPJ Breast Cancer. 2025 Jan 30;11(1):9. IF: 6.5
Understanding metastasis mixed-treatment responses through genomic analyses.
www.nature.com/articles/s41523-025-00724-z
